• Reliq Health (RHT) has announced it has signed contracts with two U.S. nephrology practices
  • The two clinics will use Reliq’s proprietary iUGO Care platform to monitor patients with chronic kidney disease
  • The company will receive an average of US$65 per month for each patient under the terms of the new contracts
  • Using the iUGO Care platform, nephrologists will be able to monitor chronic kidney disease patients at home in order to help prevent disease progression
  • Shares of Reliq Health were up 3.85 per cent to C$0.54 as of 3:59 p.m. EDT

Reliq Health (RHT) has announced it has signed contracts with two U.S. nephrology practices.

The two clinics will use Reliq’s proprietary iUGO Care platform to monitor patients with chronic kidney disease (CKD). By using the platform, nephrologists will be able to monitor patients at home in order to help prevent disease progression.

Under the terms of the contracts, Reliq will receive an average of US$65 per month for each patient treated.

“It is exciting to see the rapidly increasing demand for Reliq’s iUGO Care platform with specialists in the US,” Dr. Lisa Crossley, CEO of Reliq Health Technologies, said in a statement.

She continued, “Chronic Kidney Disease typically develops as a result of uncontrolled high blood pressure and/or diabetes. Ensuring medication compliance and managing blood pressure and blood sugar in CKD patients is critical to limiting further damage to the kidneys that could lead to End Stage Renal Disease (ESRD), dependence on dialysis, the need for a kidney transplant and ultimately death.”

Based out of Hamilton, Ontario, Reliq Health Technologies is focused on developing virtual care solutions, including ones like its iUGO platform.

The iUGO platform is geared towards community-based virtual healthcare and care coordination. It is capable of treating patients who have complex conditions with high quality care at home, including improving overall health outcomes, enhancing quality of life and reducing the cost of care delivery.

Shares of Reliq Health were up 3.85 per cent to C$0.54 as of 3:59 p.m. EDT.

More From The Market Online

Canadian biotech stock investigates potential weight loss drugs

FSD Pharma Inc. (CSE:HUGE) is expanding its pipeline into metabolic and related disorders including weight loss and liver health.
The Market Online Video

Emerging opportunity in a growing, high-value dermatological market

Kane Biotech (TSXV:KNE) engages in the development and commercialization of products that prevent and remove microbial biofilms.